|
PRMT6 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.53740353781018E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.72090017183757E-10 |
| Normal-vs-Stage2 |
5.12359999982337E-08 |
| Normal-vs-Stage3 |
2.99316127438942E-13 |
| Normal-vs-Stage4 |
4.94049245958195E-14 |
| Stage1-vs-Stage2 |
6.592200E-01 |
| Stage1-vs-Stage3 |
2.555500E-03 |
| Stage1-vs-Stage4 |
8.628500E-04 |
| Stage2-vs-Stage3 |
1.344300E-02 |
| Stage2-vs-Stage4 |
2.377200E-03 |
| Stage3-vs-Stage4 |
3.164800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.56259507742152E-12 |
| Normal-vs-AfricanAmerican |
5.89119999450105E-08 |
| Normal-vs-Asian |
1.87590054601117E-10 |
| Caucasian-vs-AfricanAmerican |
5.214200E-01 |
| Caucasian-vs-Asian |
7.843600E-01 |
| AfricanAmerican-vs-Asian |
6.605800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.37396818553771E-12 |
| Normal-vs-Female |
3.08340020183095E-11 |
| Male-vs-Female |
3.683600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.00749466733919E-11 |
| Normal-vs-Age(41-60Yrs) |
1.75589542905641E-11 |
| Normal-vs-Age(61-80Yrs) |
6.95254964711012E-12 |
| Normal-vs-Age(81-100Yrs) |
7.042300E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.177000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.795370E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.228200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.351800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.852000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.070600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.140000E-02 |
| Classical-VS-Follicular |
3.969400E-01 |
| Classical-VS-Other |
8.122600E-01 |
| Classical-VS-Normal |
1.21009979814346E-10 |
| Tall-VS-Follicular |
3.149600E-02 |
| Tall-VS-Other |
7.141600E-01 |
| Tall-VS-Normal |
8.44135872313245E-12 |
| Follicular-VS-Other |
6.522800E-01 |
| Follicular-VS-Normal |
6.44410003136642E-09 |
| Other-VS-Normal |
3.658400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.26049948256934E-10 |
| Normal-vs-N1 |
1.03406172513587E-12 |
| N0-vs-N1 |
1.330220E-02 |
|
|
